登录 | 注册    关注公众号  
微信公众号
搜索
 > 【LILRA4】

LILRA4信息

英文名称:Leukocyte immunoglobulin-like receptor subfamily A member 4
中文名称:人白细胞免疫球蛋白样受体亚家族A成员4
靶点别称:ILT7,CD85g,Immunoglobulin-like transcript 7,LILRA4,Leukocyte Immunoglobulin Like Receptor A4,Leukocyte Immunoglobulin-Like Receptor, Subfamily A (With TM Domain), Member 4,CD85 Antigen-Like Family Member G,Leucocyte Ig-Like Receptor A4,Leukocyte Immunoglobulin-Like Receptor, Subfamily A (Without TM Domain), Member 4,Leukocyte Immunoglobulin-Like Receptor Subfamily A Member 4,CD85g Antigen,ILT-7
上市药物数量:0
临床药物数量:1
最高研发阶段:临床二期

LILRA4产品列表

产品库
物种
标签
属性
ACRO质量管理体系
 
评论(0)
 

LILRA4分子别名

LILRA4,CD85g,ILT7,ILT-7

LILRA4分子背景

Leukocyte immunoglobulin-like receptor subfamily A member 4 (LILRA4/ILT7/CD85g) is a marker of plasmacytoid dendritic cells (pDCs), which are reported to be a major source of the abnormally high levels of IFNα associated with autoimmune diseases. Targeting LILRA4 with therapeutic antibodies to promote killing of these IFNα-producing pDCs is being investigated as a novel approach to alleviating the symptoms of autoimmune diseases. LILRA4 is an immunoglobulin-like protein preferentially expressed on the surface of human plasmacytoid dendritic cells (pDCs). It interacts with bone marrow stromal cell antigen 2 to control the Toll-like receptor (TLR) driven response by pDCs to viral infection. It may also be involved in modulating pDC-tumour interactions. pDCs are a source of the excess IFNα which drives autoimmune disease symptoms.

LILRA4临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Daxdilimab MEDI-7734; VIB-7734; HZN-7734 临床二期 Sbi Biotech Co Ltd, Horizon Therapeutics PLC 多发性肌炎, 盘状红斑狼疮, 肌炎, 皮肌炎, 斑秃, 皮肤红斑狼疮, Sjtoegren综合征, 系统性硬皮病, 狼疮肾炎, 系统性红斑狼疮, 急性肺损伤 详情

消息提示

请输入您的联系方式,再点击提交!

确定